Mirum Pharmaceuticals announced that Rob Myers, M.D., will succeed Joanne Quan, M.D., as Chief Medical Officer. Dr. Quan ceased serving in this role on September 2, 2026, with her employment termination expected on October 19, 2026. The separation is treated as involuntary under the company's Severance Plan, entitling Dr. Quan to standard benefits and an extension of her stock option exercise period to 12 months post-separation. Additionally, her 2026 annual target bonus will be paid at the 100% achievement level upon separation. Dr. Myers is expected to begin employment on September 21, 2026. Mirum Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development of treatments for liver diseases.

Mirum Pharmaceuticals reported second quarter 2026 net product sales of $176.2 million and raised full-year guidance to $680–$700 million. The company issued $690 million in convertible senior notes due 2032 and settled approximately 75% ($237.2 million) of its 2029 convertible notes, holding $561.3 million in unrestricted cash as of June 30, 2026. Regulatory updates include FDA Breakthrough Therapy designation for volixibat in primary sclerosing cholangitis and a pre-NDA meeting indicating a potential Phase 3 study before an H1 2027 submission. Zilurgisertib’s PDUFA date is September 26, 2026, while brelovitug topline results are expected in Q3 and Q4 2026. Mirum Pharmaceuticals operates as a rare disease company focused on liver and genetic diseases.